Literature DB >> 6585852

Sleep-related myoclonus in rheumatic pain modulation disorder (fibrositis syndrome) and in excessive daytime somnolence.

H Moldofsky, C Tullis, F A Lue, G Quance, J Davidson.   

Abstract

We describe a new syndrome, Rheumatic Pain Modulation Disorder (RPMD) ("fibrositis syndrome") with sleep-related myoclonus (involuntary periodic leg movements). Measures of sleepiness, fatigue and pain, before and after sleep, and aspects of sleep of nine subjects (Ss) with RPMD and sleep-related myoclonus were compared to nine subjects with excessive daytime somnolence and sleep-related myoclonus. In eight of the RPMD with sleep-related myoclonus and three of those with daytime sleepiness, an alpha (7.5-11 Hz) EEG Non-Rapid Eye Movement sleep disorder was demonstrated. The RPMD with sleep-related myoclonus group contained a greater number of women, more pain, morning fatigue, and disturbances in sleep (more stage changes and alpha EEG sleep prior to leg myoclonus); but in comparison to the sleep-related myoclonus, daytime somnolent group, there were no differences in evening and morning sleepiness, number of limb movements, movement arousals, awakenings after sleep onset, sleep duration, and percent sleep stages.

Entities:  

Mesh:

Year:  1984        PMID: 6585852     DOI: 10.1097/00006842-198403000-00006

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  3 in total

Review 1.  Fibromyalgia: an age-old malady begging for respect.

Authors:  R Powers
Journal:  J Gen Intern Med       Date:  1993-02       Impact factor: 5.128

2.  Clinical screening for narcolepsy/cataplexy in patients with fibromyalgia.

Authors:  P Disdier; P Genton; G Bolla; D Verrot; C Christides; J R Harlé; P J Weiller
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

3.  Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo.

Authors:  H Vaerøy; A Abrahamsen; O Førre; E Kåss
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.